Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 2/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | TEAD4 | Q15561 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.42 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.42 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41818 | 0.84 | KDM4E (0.42) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL8477207 | 0.81 | KDM4E (0.46) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL13078827 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL4526286 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| Acetic Acid SCHEMBL14990893 | 0.78 | KDM4E (0.39) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL8482842 | 0.78 | ALOX15 (0.49) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL3558568 | 0.78 | KDM4E (0.65) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL8663329 | 0.77 | KDM4E (0.69) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL6396507 | 0.77 | KDM4E (0.48) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL6396514 | 0.77 | KDM4E (0.48) | KDM4EALDH1A1POLBTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4074709-A1 | MONOCYCLIC BETA-LACTAM COMPOUND AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021115444-A1 | MONOCYCLIC β-LACTAM COMPOUND AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| EP-1967515-A1 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2008-09-10 | — | — | EP | disclosed |
| EP-1967515-A1 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2008-09-10 | — | — | EP | disclosed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| WO-2007138048-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1862459-A1 | Novel heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1862459-A1 | Novel heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-5075299-A | CEPHALOSPORIN COMPOUNDS AND ANTIBACTERIAL AGENTS | MEIJI SEIKA KAISHA, LTD. (JP) | 1991-12-24 | — | — | US | disclosed |
| EP-0354576-A2 | Novel cephalosporin compounds and antibacterial agents | MEIJI SEIKA KAISHA LTD. (JP) | 1990-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CYP4B1, CYP3A4, G6PD | KDM4E 907/4885ALDH1A1 712/4885POLB 2566/4885 |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CYP4B1, CYP2C19, CYP3A4 | KDM4E 115/4885ALDH1A1 812/4885POLB 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.